Envista Holdings Corp (NVST)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Ticker
NVST
Exchange
NYSE
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$4.03B
52-week range
$18.77 - $30.42

Valuation

Share price
$25.17 (close of Nov 6, 2026)
P/E (TTM)
6.40x
Price to book
1.31x
Price to free cash flow
16.67x
Enterprise value
$4.46B
Book value per share
$19.27

Price performance

PeriodChange
1 day+0.84%
5 days+7.06%
1 month+8.17%
3 months-8.07%
6 months-7.02%
Year to date+15.94%
1 year+29.21%
3 years+18.00%
5 years-41.92%
All time-9.95%

Short interest

As of
Oct 15, 2026
Short % of float
6.83%
Shares short
9.77M
Days to cover
4.09
Change since prior report
-19.04%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
1.51%
Return on invested capital
2.30%
Return on assets
0.83%
Return on capital employed
4.48%
Gross margin
54.67%
Net margin
1.73%
EBITDA margin
12.21%
Revenue growth
8.32%
Free cash flow growth
-23.89%

Cash flow and balance sheet

Free cash flow yield (TTM)
6.00%
Current ratio
2.45x
Net debt to EBITDA
0.49x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$2.72B
Cost of revenue
$1.23B
Gross profit
$1.49B
EBITDA
$332.10M
Net income
$47.00M
Earnings per share
$0.28
Research and development
$114.00M
Interest expense
$36.60M
Shares outstanding
168.00M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$2.72B$1.49B$47.00M$0.28
2024-12-31$2.51B$1.37B-$1.12B-$6.50
2023-12-31$2.57B$1.44B-$100.20M-$0.60
2022-12-31$2.57B$1.47B$243.10M$1.49
2021-12-31$2.51B$1.43B$340.50M$2.11
2020-12-31$1.93B$1.05B$33.30M$0.21
2019-12-31$2.28B$1.35B$217.60M$1.60
2018-12-31$2.84B$1.60B$230.70M$1.80
2017-12-31$2.81B$1.62B$301.10M$2.35
2016-12-31$2.79B$1.61B$272.00M-

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3154.67%1.73%1.51%2.30%
2024-12-3154.68%-44.56%-38.12%-23.16%
2023-12-3156.13%-3.90%-2.40%0.27%
2022-12-3157.41%9.46%5.78%4.76%
2021-12-3156.86%13.57%8.39%5.55%
2020-12-3154.68%1.73%0.89%0.76%
2019-12-3159.05%9.52%6.14%3.66%
2018-12-3156.31%8.11%4.78%4.54%
2017-12-3157.68%10.71%--
2016-12-3157.92%9.77%--

Cash and debt by year

Period endCashDebt
2025-12-31$1.21B$1.45B
2024-12-31$1.07B$1.28B
2023-12-31$940.00M$1.40B
2022-12-31$606.90M$870.70M
2021-12-31$1.07B$883.40M
2020-12-31$888.90M$907.70M
2019-12-31$211.20M$1.32B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$230.40M$37.60M
2024-12-31$302.70M$35.30M
2023-12-31$217.50M$30.70M
2022-12-31$107.00M$30.50M
2021-12-31$306.90M$28.20M
2020-12-31$236.20M$22.60M
2019-12-31$319.70M$18.40M
2018-12-31$327.90M$13.30M
2017-12-31$310.20M$12.30M
2016-12-31$367.90M$10.50M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$0.35
2026-08-05Jun 2026$0.33
2026-05-06Mar 2026$0.31
2026-02-05Dec 2025$0.32
2025-10-29Sep 2025$0.27
2025-07-31Jun 2025$0.24
2025-05-01Mar 2025$0.20
2025-02-05Dec 2024$0.23

Filings and sources

Company website
envistaco.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · Medline Inc. (MDLN) · ResMed Inc (RMD) · Alcon Inc (ALC) · West Pharmaceutical Services Inc (WST) · Solventum Corp (SOLV) · Baxter International Inc (BAX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades